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a  b  s  t  r  a  c  t
Aberrant  regulation  of phosphatidylinositol-3-kinases  (PI3Ks)  is  known  to  be involved  in  the  progression
of  cancers.  PI3K-binding  ﬂavonoids  such  as  quercetin  and  myricetin  have  been  shown  to  inhibit PI3K
activity,  but  the  direct  targeting  of  ﬁsetin  to PI3K  has  not  been  established.  Here,  we  carried  out  an  in
silico  investigation  of ﬁsetin  binding  to PI3K  and  determined  ﬁsetin’s  inhibitory  activity  in  enzymatic
and  cell-based  assays.  In  addition,  ﬁsetin  induced  apoptosis  in  human  Burkitt’s  lymphoma  Raji cells  by
inhibiting  both  PI3Ks  and  mammalian  target  of  rapamycin  (mTOR).  Our  results  indicate  that ﬁsetin  may




treatment  of cancer.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).poptosis
urkitt’s lymphoma
. Introduction
Phosphatidylinositol-3-kinases (PI3Ks) constitute a family of
ipid kinases characterized by their ability to phosphorylate the 3′-
H group on the inositol ring of inositol phospholipids to generate
he second messenger phosphatidylinositol-3,4,5-trisphosphate.
I3Ks participate in various cellular functions, including prolifer-
tion, migration, and survival, by regulating the phosphorylation
f Akt. Aberrant regulation of PI3K has been implicated in the
nduction and progression of several diseases, including cancer
44]; PI3K-mediated cell growth, proliferation, malignant transfor-
ation, and resistance to apoptosis have all been reported to be
onnected with hyperactivation of Akt [18,47]. PI3K is well known
o be critically involved in lymphocyte growth and survival dur-
ng B-cell tumor immortalization [1,5,6,9,14,19,36,42]. Therefore,
s expected, inhibitors of the PI3K/Akt pathway induce apoptosis
n leukemia, lymphoma, and myeloma cells [20].
Fisetin (3, 7, 3′, 4′-tetrahydroxy ﬂavone; Fig. 1A) is commonly
ound in various fruits (e.g. strawberries and grapes) and vegeta-
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c-nd/4.0/).bles (e.g. onions and cucumbers) at concentrations of 2–160 g/g
[16,23,33,41]. Several studies have demonstrated ﬁsetin’s wide
variety of activities, which include anti-proliferative, anti-oxidant,
anti-angiogenic, and anti-cancer activities [22,24,29,38,43,52–54].
Fisetin belongs to the same ﬂavonol subgroup as PI3K-binding
ﬂavonoids such as quercetin and myricetin [48]. Interestingly,
ﬁsetin exhibits anti-metastatic potential accompanied by the inhi-
bition of PI3K protein expression in prostate cancer cells [8], but
its direct targeting of PI3Ks and its anti-cancer activity in blood
cancer cells have not been established. Therefore, in this study,
we carried out an in silico investigation of the binding of ﬁsetin
to PI3K and evaluated whether ﬁsetin inhibited PI3K activity at the
enzymatic and cellular levels in human B lymphoma Raji cells. The
pro-apoptotic activity of ﬁsetin and its inhibition of mammalian
target of rapamycin (mTOR) in Raji cells were also assessed to pro-
vide insight into the possibility of using ﬁsetin as an initial backbone
for the development of dual inhibitors of PI3Ks and mTOR.
2. Materials and methods2.1. Materials
Fisetin was  purchased from Sigma–Aldrich (MO), dissolved in
dimethyl sulfoxide (DMSO) as 30 mM stock, and stored at −20 ◦C.
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Fig. 1. Fisetin targets and inhibits PI3K activity. (A) Chemical structure of ﬁsetin.
(B)  Proposed binding mode of ﬁsetin (green) to the ATP-binding pocket of PI3K.
PI3K  and interacting residues are represented by ribbons and sticks, respectively.
Hydrogen-bonding interactions appear as dashed yellow lines; all hydrogen atoms
except those involved in hydrogen bonding were omitted for clarity. (C) Assay of
PI3K  kinase activity in the presence of ﬁsetin (Materials and methods). *P < 0.05;
**P  < 0.01; ***P < 0.001. (D) Immunoblotting assay of PI3K activity (Materials and
methods).orts 2 (2015) 984–989 985
Mouse F(ab’) 2 anti-human -immunoglobulin M (-IgM,  chain
speciﬁc) was  purchased from Southern Biotech (AL).
2.2. Computational modeling
Molecular docking analysis was  performed using the Maestro
modeling environment (Schrödinger, CA). The crystal structure of
human PI3K (PDB: 1E8Y; [48] was  preprocessed with the Pro-
tein Preparation Wizard by adding hydrogens, removing water
molecules, assigning partial charges using the OPLS 2005 force
ﬁeld and protonation states, and restraining minimization. All opti-
mized ligands were prepared using LigPrep, which veriﬁes proper
ionization states, tautomeric forms, stereochemistry, and ring con-
formations.
Based on a grid box of 20 Å × 20 Å × 20 Å, ligands were docked
into the active site of PI3K using Glide in Extra Precision (XP)
mode. All default parameters were used for XP docking. To account
for ﬂexibility in both the ligand and the receptor, we  employed the
Induced Fit Docking (IFD) protocol implemented in Maestro. All
residues within 5.0 Å of ligand poses were included in the Prime
reﬁnement. Each ligand was re-docked into every reﬁned active
site of PI3K in Glide XP mode with a van der Waals scaling of 0.50
for both protein and ligand non-polar atoms.
2.3. Assay of kinase activity
PI3K activity was  assayed in Millipore (CA). Brieﬂy, human
PI3K isoforms were diluted in buffer consisting of 20 mM
3-(N-morpholino)propanesulfonic acid, 1 mM ethylenediaminete-
traacetic acid (EDTA), 0.01% Brij-35, 5% glycerol, 0.1% -
mercaptoethanol, and 1 mg/mL  bovine serum albumin and mixed
with the reaction mixture containing the compound. The reaction
was initiated by adding the Mg-ATP mix. After incubation for 30 min
at room temperature, the reaction was  stopped by adding stop solu-
tion containing EDTA and biotinylated phosphatidylinositol-3,4,5-
trisphosphate. Finally, the solution was exposed to detection buffer,
which contains europium-labeled anti-glutathione S-transferase
monoclonal antibody, glutathione S-transferase-tagged GRP1
pleckstrin homology domain, and streptavidin-allophycocyanin.
The plate was read in time-resolved ﬂuorescence mode and the
homogenous time-resolved ﬂuorescence signal was  calculated as
10,000 × (emission at 665 nm/emission at 620 nm).
2.4. Cell culture
All materials for cell culture were purchased from Hyclone (UT).
Human B lymphoma Raji cells were purchased from American
Type Culture Collection (VA). Cells were cultured in RPMI 1640
medium supplemented with 10% heat-inactivated fetal bovine
serum, 100 U/mL penicillin, and 100 g/mL streptomycin in a
humidiﬁed atmosphere of 5% CO2 at 37 ◦C.
2.5. Cell-based PI3K assay
Raji cells were seeded at density of 1 × 106/mL  and cultured for
24 h. Cells were pre-treated with ﬁsetin at the indicated concentra-
tions for 90 min  and treated with -IgM (0.25 g/mL) for 30 min.
Then, proteins were prepared for immunoblotting in order to detect
the levels of phosphorylated Akt (p-Akt).
2.6. ImmunoblottingRaji cells were seeded at density of 1 × 106/mL and cultured
for 24 h. Cells were treated with ﬁsetin for the indicated times
and harvested, rinsed with cold phosphate-buffered saline (Gibco,
NY), and lysed with RIPA buffer (Elpis Biotech, Korea; 50 mM























































Chemical structures and docking scores for selected ﬂavonols.
Compounda R1 R2 R3 R4 R5 XPa IFDb
Fisetin H H H OH OH −11.00 −1845.11
Myricetin OH H OH OH OH −12.49 −1847.62
Quercetin OH H OH OH H −11.90 −1846.74
Morin OH OH H OH H −10.74 −1843.82
Kaempferol OH H H OH H −10.73 −1843.29
Galangin OH H H H H −10.56 −1842.78
a Glide XP docking scores computed with rigid docking in which only ligands are
considered ﬂexible; the protein is kept ﬁxed during docking.86 J.Y. Lim et al. / Toxicolo
ris–HCl [pH 8.0], 5 mM EDTA, 150 mM NaCl, 1% NP-40, and 1 mM
henylmethanesulfonylﬂuoride). After incubation on ice for 1 h and
entrifugation at 18,000 × g for 15 min  at 4 ◦C, the protein content
f the supernatant was quantiﬁed with the RC DC Protein Assay Kit
Bio-Rad, CA). Proteins were mixed with 5 × sample buffer (Elpis
iotech; 0.375 M Tris–HCl [pH 6.8], 5% sodium dodecyl sulfate, 5%
-mercaptoethanol, 50% glycerol, and 0.05% bromophenol blue),
enatured by boiling at 100 ◦C for 5 min, loaded onto a 10% sodium
odecyl sulfate polyacrylamide gel, separated via electrophoresis,
nd transferred to a polyvinylidene diﬂuoride membrane (Milli-
ore). The membrane was washed with TBST (10 mM Tris–HCl [pH
.5], 150 mM NaCl, and 0.1% Tween-20), blocked with TBST contain-
ng 5% skim milk (BD Difco, NJ), and incubated with 1:1000 primary
ntibody at 4 ◦C overnight. After three washes with TBST for 30 min,
he membrane was incubated with secondary antibody conjugated
o horseradish peroxidase (Santa Cruz Biotechnology, CA) for 2 h.
fter another three washes with TBST for 30 min, the membrane
as developed using Pierce SuperSignal West Femto Maximum
ensitivity Substrate (Fisher Scientiﬁc, PA) in a LAS-3000 Lumi-
escent Image Analyzer (Fuji Photo Film Co., Ltd., Japan). Primary
ntibodies against p-Akt (S473 or T308), Akt, p-mTOR (S2448),
TOR, p-p70S6K (S371), p-p70S6K (T389), p-4E-BP1 (T37/46), p-
istone H2A.X (H2A.X, S139), and Bax were purchased from Cell
ignaling Technology Inc. (MA). Primary antibodies against actin,
IAP-2, and cIAP-1 were purchased from Santa Cruz Biotechnol-
gy. Primary antibodies against Bcl-2, Bcl-x, Bad, and Bak were
urchased from Epitomics (CA). Actin was used as a loading control.
.7. Assay of cell viability
Cells (1 × 104/well) were seeded, incubated in a 96-well plate
or 24 h, and treated with ﬁsetin or vehicle control (0.1% DMSO)
or an additional 24, 48, or 72 h. Cell viability was subsequently
etermined with the EZ-CYTOX Kit (Dogen, Korea) according to the
anufacturer’s protocol. Absorbance was measured with a Wallac
nVision microplate reader (PerkinElmer, Finland). All experiments
ere performed in triplicate.
.8. Analysis of apoptosis
Cells (1 × 106/well) were plated in a 6-well plate, incubated for
4 h, and treated with ﬁsetin or vehicle control (0.1% DMSO) for
n additional 24, 48, or 72 h. Then, cells were harvested, subjected
o the Muse Annexin V and Dead Cell Assay Kit (Millipore), and
valuated with the Muse Cell Analyzer (Millipore) according to the
anufacturer’s protocol.
.9. Statistical analysis
Data are presented as mean ± standard deviation. Signiﬁcance
as determined using Student’s t test (two-tailed) and differences
ere considered signiﬁcant when P < 0.05.
. Results and discussion
.1. Fisetin targets PI3K and inhibits its activity
The hypothesis that ﬁsetin directly binds PI3K was  computa-
ionally evaluated in comparison with other members of ﬁsetin’s
avonol subgroup, which includes PI3K-binding ﬂavonoids such as
uercetin and myricetin [48]. Fisetin exhibited a binding mode that
as similar to that of the quercetin crystal structure (Fig. 1B). The
3 hydroxyl and C4 carbonyl groups of ﬁsetin formed two hydrogen
onds with E880 and V882 at the hinge region. The C3 substituent
as critical to the binding of ﬁsetin to the active site of PI3K, as it
ormed two bivalent hydrogen bonds with K833, D841, and D964. Inb IFD scores computed with the IFD protocol for protein ﬂexibility. Docking scores
indicate how well the ligands are predicted to bind to the target.
addition, the Glide XP and IFD scores of ﬁsetin were comparable to
those of quercetin and myricetin (Table 1). These observations sug-
gest that ﬁsetin may  bind in a mode analogous to that of quercetin
to PI3K. Fisetin inhibited the kinase activities of PI3K, ,  and  in a
dose-dependent manner and weakly inhibited the activity of PI3K
only at 10 M (Fig. 1C).
The inhibitory effect of ﬁsetin on anti-IgM-induced activation
of PI3K was  evaluated in Raji cells. IgM, an antigen receptor on
B lymphocytes, is a membrane-bound immunoglobulin [15,46];
immunoglobulin cross-linking on the cell surface triggers B cells to
proliferate and differentiate by activating kinases, including PI3Ks
[3,7,39]. Therefore, in Raji cells, the anti-IgM-stimulated phospho-
rylation of Akt at T308 and/or S473 enables assessment of the
ability of compounds to inhibit PI3K [49,51]. Here, ﬁsetin inhib-
ited anti-IgM-stimulated phosphorylation of Akt in Raji cells in a
dose-dependent manner (Fig. 1D).
All isoforms of PI3K are expressed in exponentially growing Raji
cells, but the  and  isoforms are more highly expressed than
the  and  isoforms [49]. In addition, since PI3K activity was
recently suggested to predominate in Raji cells [49], PI3K may
be a major target via which ﬁsetin induces the apoptosis of Raji
cells, although ﬁsetin inhibited the enzymatic activity of all iso-
forms of PI3K (Fig. 1C). Given that the sensitivity of Raji cells to
chemotherapy was previously enhanced by blocking the PI3K/Akt
pathway [12], the phytochemical ﬁsetin may  enhance chemother-
apeutic efﬁcacy in patients with B cell lymphoma.
3.2. Fisetin induces apoptosis in Raji cells
Fisetin signiﬁcantly inhibited cell viability and induced apo-
ptosis in Raji cells in a time- and dose-dependent manner
(Fig. 2A–B). Fisetin has been shown to induce apoptosis in human
promyeloleukemic cells and nonsmall lung cancer cells accompa-
nied by the speciﬁc downregulation of anti-apoptotic molecules
and via a mitochondria-mediated pathway, respectively [21,25].
To better understand the pro-apoptotic action of ﬁsetin on
Raji cells, we applied a proteome array of 35 antibodies against
apoptosis-related proteins. We  observed decreased protein expres-
sion of cIAP-2 after 30 M ﬁsetin exposure for 24 and 72 h (data not
shown). However, the levels of other anti/pro-apoptotic proteins,
such as cIAP-1 and Bcl-2 family members, were not changed by
ﬁsetin treatment (data not shown). The downregulation of cIAP-2
by ﬁsetin at 30 M was conﬁrmed via immunoblotting (Fig. 2C).
J.Y. Lim et al. / Toxicology Reports 2 (2015) 984–989 987

















So  determine the number of apoptosis cells stained with Annexin V and propidium
setin  on the expression levels of apoptosis-related proteins.
mmunoblotting also conﬁrmed that there were no ﬁsetin-induced
hanges in the levels of other anti/pro-apoptotic proteins (Fig. 2C).
isetin speciﬁcally downregulated the expression of anti-apoptotic
olecule, induced myeloid leukemia cell differentiation protein
n the apoptotic process of HL-60 human myelogenous leukemia
ells [25], and here it speciﬁcally downregulated the expression
f cIAP-2. In addition, the pharmacological inhibition of PI3K has
een shown to exhibit the downregulation of cIAP-2, suggesting
hat apoptotic ﬁsetin in Raji cells could speciﬁcally downregulate
he expression of cIAP-2 via its potential to inhibit PI3K [17,35].
.3. Fisetin inhibits mTOR activity
In several previous studies, dual inhibition of PI3K and mTOR
ignaling effectively suppressed cancer progression [30,37]. The
TOR pathway appears to be critical to lymphomagenesis; its aber-
ant activation was detected in Burkitt’s lymphoma [2,11,32,40].
everal drug candidates have been shown to inhibit the cat- relative to the total number of cells analyzed. (C) Immunoblotting of the effect of
alytic subunits of both PI3K and mTOR, which contain structural
similarities [31]. For example, the PI3K inhibitors LY294002 and
NVP-BKM120 also inhibited mTOR [27,45]. Several clinical tri-
als have implemented combined inhibition of PI3K and mTOR to
ensure the synergistic efﬁcacy of drug candidates for the treat-
ment of cancers [4,10,34]). Therefore, we  tested whether ﬁsetin
inhibits mTOR at 30 M.  As shown in Fig. 3, ﬁsetin strongly inhib-
ited the phosphorylation of mTOR (S2448) and its downstream
targets p70S6K (S371 and T389) and 4E-BP1 (T37/46). Thus, in
addition to ﬁsetin’s inhibition of PI3K, its inhibition of mTOR  may
enhance apoptosis in Raji cells [13,26].
We also examined the effect of ﬁsetin on expression of the DNA-
damage marker H2A.X because ﬁsetin has been shown to induce
DNA damage and apoptosis at high concentrations between 50
and 250 M in blood cancers [28,50]. The levels of H2A.X pro-
tein increased over time in the presence of 30 M ﬁsetin (Fig. 3),
suggesting the involvement of DNA damage in the pro-apoptotic
activity of ﬁsetin on Raji cells.
988 J.Y. Lim et al. / Toxicology Rep
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. Conclusion
In summary, we determined that ﬁsetin targets PI3K, inhibits its
ctivity at the enzymatic and cellular levels, and induces apoptosis
n Raji cells via the downregulation of cIAP-2 protein expression.
he pro-apoptotic activity of ﬁsetin may  be linked to a potential to
nhibit mTOR signaling and to induce DNA damage. Since ﬁsetin
xhibits a wide variety of activities, including anti-proliferative,
nti-oxidant, anti-angiogenic, and anti-cancer activities, it may
rovide a natural backbone for the development of novel dual
nhibitors of PI3Ks and mTOR for the treatment of patients with
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